Preliminary evidence of anxiolytic effects of the CRF1 receptor antagonist R317573 in the 7.5% CO2 proof-of-concept experimental model of human anxiety
Open accessThe DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
We have validated the use of prolonged inhalation of 7.5% carbon dioxide (CO 2) as a human model of anxiety and have shown that drugs from two prototypical classes of anxiolytics, benzodiazepines and a serotonin reuptake inhibitor, attenuate CO 2-induced symptoms ( Bailey et al., 2007a ). Preclinical evidence suggests that drugs acting at the corticotropin-releasing factor (CRF) system may be useful for the treatment of depression, anxiety, and other stress-related disorders ( Valdez, 2006 ), hence we have now examined the effects of a CRF 1 receptor antagonist in the 7.5% CO 2 model. In a randomized double-blind, placebo-controlled, study in 32 healthy participants we examined the effects of 7 days of treatment with the CRF 1 receptor antagonist, R317573, at a dose that shows a favourable safety profile and is comparable with those effective in preclinical models (40 mg). On day 8, eight of the placebo-treated group received lorazepam (LZP) 2 mg as a positive control. All participants underwent 20 min inhalation of 7.5% CO 2-enriched air. Subjective reports of peak gas effects were assessed using visual analogue scales and questionnaires. The mean age of participants was 26 years, and 13 were male. The peak effects of CO 2 were expressed as a difference from baseline scores obtained while breathing air alone. Compared with placebo (PLAC), both drug groups showed a decrease in all subjective symptoms, total score on the panic symptom inventory (CRF 11 [2.6], PLAC 16.4 [3.1], LZP 2.9 [3.0]) and a generalized anxiety disorder symptom scale (CRF 2.2 [1.5], PLAC 8.2 [2.2], LZP 1.1 [1.5]). We have shown that a drug that acts to inhibit the CRF 1 receptor shows efficacy in the 7.5% CO 2 model of anxiety in healthy participants.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Binneman, B., Feltner, D., Kolluri, S., Shi, Y., Qiu, R., & Stiger, T. (2008) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2008.07071199 · Cited by 254 · cited 2×
“…studies, particularly in the treatment of anxiety and depression (Ising and Holsboer, 2007), although this evidence is not consistent, with a recent report showing lack of efficacy of a different antagonist in major depression (Binneman et al., 2008) and more recently in GAD (Coric et al., 2010).”
Result
Cited by
Pharmacotherapy of Anxiety Disorders: Current and Emerging Treatment Options
Garakani, A., Murrough, J. W., Freire, R. C., Thom, R. P., Larkin, K., Buono, F. D., & Iosifescu, D. V. (2020) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2020.595584 · Cited by 440
Bandelow, B., Baldwin, D., Abelli, M., Bolea-Alamanac, B., Bourin, M., Chamberlain, S. R., Cinosi, E., Davies, S., Domschke, K., Fineberg, N., et al. (2017) · The World Journal of Biological Psychiatry · doi:10.1080/15622975.2016.1190867 · Cited by 347
Self-citationDon’t stress about CRF: assessing the translational failures of CRF1antagonists
Spierling, S. R., & Zorrilla, E. P. (2017) · Psychopharmacology · doi:10.1007/s00213-017-4556-2 · Cited by 170
Brain and gut CRF signaling: biological actions and role in the gastrointestinal tract
Tache, Y., Larauche, M., Yuan, P.-Q., & Million, M. (2018) · Current Molecular Pharmacology · doi:10.2174/1874467210666170224095741 · Cited by 147
“5% CO2 for 20 min, the CRF-R1 antagonist R317573 (40 mg once daily) given for 7 days significantly dampened panic symptom score and generalized anxiety compared to placebo [292].”
BackgroundDunlop, B. W., Binder, E. B., Iosifescu, D., Mathew, S. J., Neylan, T. C., Pape, J. C., Carrillo-Roa, T., Green, C., Kinkead, B., Grigoriadis, D., et al. (2017) · Biological Psychiatry · doi:10.1016/j.biopsych.2017.06.024 · Cited by 96
Metadata
- Authors
- Bailey, J. E., Papadopoulos, A., Diaper, A., Phillips, S., Schmidt, M., van der Ark, P., Dourish, C. T., Dawson, G. R., & Nutt, D. J.
- Venue
- Journal of Psychopharmacology
- Publisher
- SAGE Publications
- Published
- 2011-05-09
- Volume
- 25
- Issue
- 9
- Pages
- 1199-1206
- ISSN
- 0269-8811 (ISSN-L)
- 1461-7285
- OpenAlex
- W2033909710
- Cited by
- 55
- References
- 1
- FWCI
- 2.58
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Preliminary evidence of anxiolytic effects of the CRF1 receptor antagonist R317573 in the 7.5% CO2 proof-of-concept experimental model of human anxiety. https://app.cochat.ai/papers/10.1177/0269881111400650
- The paper
- Bailey, J. E., Papadopoulos, A., Diaper, A., Phillips, S., Schmidt, M., van der Ark, P., Dourish, C. T., Dawson, G. R., & Nutt, D. J. (2011). Preliminary evidence of anxiolytic effects of the CRF1 receptor antagonist R317573 in the 7.5% CO2 proof-of-concept experimental model of human anxiety. Journal of Psychopharmacology. https://doi.org/10.1177/0269881111400650
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.